OncLive® On Air

S19 Ep14: Board Review 2026: Top Hematology/Oncology Topics to Know

S19 Ep13: Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC

First-line treatment for metastatic non-small cell lung cancer requires moving beyond PD-L1 expression to address the needs of patients with squamous histology, brain metastases, or specific co-occurring mutations like STK11 and KEAP1. Dual immunotherapy regimens, particularly the ipilimumab and nivolumab combination, ...

S19 Ep12: Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer

Describing a tumor simply as "MET positive" is insufficient for modern non-small cell lung cancer treatment, as distinct MET aberrations require specific diagnostic assays and targeted therapies. MET protein overexpression, identified via immunohistochemistry (IHC) with 3+ staining in over 50% of cells, determines elig...

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

S19 Ep5: Navigating Patient-Centric Treatment Administration Strategies in Myeloma

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia

S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma

S18 Ep51: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape

S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings

S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma

S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML